BRAF and neoplasm: Hypermethylation assays and BRAF V600E mutation testing of tumor DNA can be used to distinguish an MSI-H tumor with absent MLH1 expression caused by hypermethylation of the MLH1 promoter from a tumor caused by a germ-line MLH1 mutation.